Is gratinumab effective when used alone?

Glofitamab (Glofitamab) is a new bispecific monoclonal antibody developed by Roche. Its unique design is that it targets CD3 on the surface of T cells and CD20 on the surface of B cells at the same time. This mechanism, called T-cell engager, can "guide" T cells in the immune system to malignant B cells, stimulating them to produce an immune attack response, thereby achieving anti-tumor effects. It is different from previous monoclonal antibodies or chemotherapy mechanisms, embodying a highly precise treatment strategy that activates immunity rather than directly killing.

So, is gratinumab effective when used alone? The answer is yes. According to the current multiple overseas clinical studies and real-world application feedback, gaffetuzumab has shown good efficacy as a single-agent therapy in patients with relapsed or refractory large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). Even if the patient has previously received multiple lines of treatment or even failed CAR-T therapy, gaffetuzumab alone can still induce remission. Its rapid onset of action, controllable toxicity and immune durability provide strong support for its monotherapy.

One of the advantages of using gratinumab as a single agent is that the treatment structure is simplified and the accumulation of adverse reactions caused by complex combinations of drugs is avoided. In addition, it uses fixed cycles of treatment rather than indefinite maintenance. Patients can stop taking the drug if they achieve remission after a certain course of treatment, which has obvious advantages in improving quality of life and reducing total medical costs.

It is worth noting that in order to reduce the risk of cytokine release syndrome (CRS), pretreatment with obinutuzumab is usually required before treatment with gaffetuzumab to first deplete some peripheral B cells, thereby reducing the inflammatory storm caused by sudden activation of the immune system. This strategy does not belong to combination therapy, but is a preliminary step for optimizing the efficacy of single drugs.

Reference materials:https://www.drugs.com/glofitamab.html